Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vallon Pharmaceuticals, Inc. VLON NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Intrinsic Value
N/A
Negative cash flow

Vallon Pharmaceuticals, Inc. (VLON) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

VLON Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Vallon Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

IMNM
IMNM
Immunome, Inc.
$22.90
+1.24%
 ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 PALI
PALI
Palisade Bio, Inc.
$2.06
+3.52%
 FHTX
FHTX
Foghorn Therapeutics Inc.
$4.85
+3.41%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 CLNN
CLNN
Clene Inc.
$6.68
+3.01%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message